Selected research
Industry Research
Angiopoietin 2 Industry Research Report 2026
Market perspective
The global Angiopoietin 2 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Angiopoietin 2 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Angiopoietin 2 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Angiopoietin 2 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Angiopoietin 2 include Eli Lilly and Company, Amgen Inc., Synergys Biotherapeutics, Inc., Silence Therapeutics Plc, RXi Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., MedImmune, LLC, F. Hoffmann-La Roche Ltd. and Boehringer Ingelheim GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Angiopoietin 2 market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Angiopoietin 2 Market by Company
Eli Lilly and Company
Amgen Inc.
Synergys Biotherapeutics, Inc.
Silence Therapeutics Plc
RXi Pharmaceuticals Corporation
Regeneron Pharmaceuticals, Inc.
MedImmune, LLC
F. Hoffmann-La Roche Ltd.
Boehringer Ingelheim GmbH
AnGes MG, Inc.
Angiopoietin 2 Segment by Type
Atu-111
BI-836880
LY-3127804
MEDI-3617
Others
Angiopoietin 2 Segment by Application
Hospital
Clinic
Others
Angiopoietin 2 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiopoietin 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angiopoietin 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiopoietin 2.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Angiopoietin 2 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Angiopoietin 2 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Angiopoietin 2 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Atu-111
- BI-836880
- LY-3127804
- MEDI-3617
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Eli Lilly and Company
- Amgen Inc.
- Synergys Biotherapeutics, Inc.
- Silence Therapeutics Plc
- RXi Pharmaceuticals Corporation
- Regeneron Pharmaceuticals, Inc.
- MedImmune, LLC
- F. Hoffmann-La Roche Ltd.
- Boehringer Ingelheim GmbH
- AnGes MG, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Angiopoietin 2 Market Size (2021-2032)
- 2.2.2 Global Angiopoietin 2 Sales (2021-2032)
- 2.2.3 Global Angiopoietin 2 Market Average Price (2021-2032)
- 2.3 Angiopoietin 2 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Atu-111
- 2.3.3 BI-836880
- 2.3.4 LY-3127804
- 2.3.5 MEDI-3617
- 2.3.6 Others
- 2.4 Angiopoietin 2 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Angiopoietin 2 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Angiopoietin 2 Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Angiopoietin 2 Revenue of Manufacturers (2021-2026)
- 3.4 Global Angiopoietin 2 Average Price by Manufacturers (2021-2026)
- 3.5 Global Angiopoietin 2 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Angiopoietin 2, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Angiopoietin 2, Product Type & Application
- 3.8 Global Manufacturers of Angiopoietin 2, Established Date
- 3.9 Global Angiopoietin 2 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eli Lilly and Company
- 4.1.1 Eli Lilly and Company Company Information
- 4.1.2 Eli Lilly and Company Business Overview
- 4.1.3 Eli Lilly and Company Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eli Lilly and Company Angiopoietin 2 Product Portfolio
- 4.1.5 Eli Lilly and Company Recent Developments
- 4.2 Amgen Inc.
- 4.2.1 Amgen Inc. Company Information
- 4.2.2 Amgen Inc. Business Overview
- 4.2.3 Amgen Inc. Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amgen Inc. Angiopoietin 2 Product Portfolio
- 4.2.5 Amgen Inc. Recent Developments
- 4.3 Synergys Biotherapeutics, Inc.
- 4.3.1 Synergys Biotherapeutics, Inc. Company Information
- 4.3.2 Synergys Biotherapeutics, Inc. Business Overview
- 4.3.3 Synergys Biotherapeutics, Inc. Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Synergys Biotherapeutics, Inc. Angiopoietin 2 Product Portfolio
- 4.3.5 Synergys Biotherapeutics, Inc. Recent Developments
- 4.4 Silence Therapeutics Plc
- 4.4.1 Silence Therapeutics Plc Company Information
- 4.4.2 Silence Therapeutics Plc Business Overview
- 4.4.3 Silence Therapeutics Plc Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Silence Therapeutics Plc Angiopoietin 2 Product Portfolio
- 4.4.5 Silence Therapeutics Plc Recent Developments
- 4.5 RXi Pharmaceuticals Corporation
- 4.5.1 RXi Pharmaceuticals Corporation Company Information
- 4.5.2 RXi Pharmaceuticals Corporation Business Overview
- 4.5.3 RXi Pharmaceuticals Corporation Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 RXi Pharmaceuticals Corporation Angiopoietin 2 Product Portfolio
- 4.5.5 RXi Pharmaceuticals Corporation Recent Developments
- 4.6 Regeneron Pharmaceuticals, Inc.
- 4.6.1 Regeneron Pharmaceuticals, Inc. Company Information
- 4.6.2 Regeneron Pharmaceuticals, Inc. Business Overview
- 4.6.3 Regeneron Pharmaceuticals, Inc. Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Regeneron Pharmaceuticals, Inc. Angiopoietin 2 Product Portfolio
- 4.6.5 Regeneron Pharmaceuticals, Inc. Recent Developments
- 4.7 MedImmune, LLC
- 4.7.1 MedImmune, LLC Company Information
- 4.7.2 MedImmune, LLC Business Overview
- 4.7.3 MedImmune, LLC Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 MedImmune, LLC Angiopoietin 2 Product Portfolio
- 4.7.5 MedImmune, LLC Recent Developments
- 4.8 F. Hoffmann-La Roche Ltd.
- 4.8.1 F. Hoffmann-La Roche Ltd. Company Information
- 4.8.2 F. Hoffmann-La Roche Ltd. Business Overview
- 4.8.3 F. Hoffmann-La Roche Ltd. Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 F. Hoffmann-La Roche Ltd. Angiopoietin 2 Product Portfolio
- 4.8.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.9 Boehringer Ingelheim GmbH
- 4.9.1 Boehringer Ingelheim GmbH Company Information
- 4.9.2 Boehringer Ingelheim GmbH Business Overview
- 4.9.3 Boehringer Ingelheim GmbH Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Boehringer Ingelheim GmbH Angiopoietin 2 Product Portfolio
- 4.9.5 Boehringer Ingelheim GmbH Recent Developments
- 4.10 AnGes MG, Inc.
- 4.10.1 AnGes MG, Inc. Company Information
- 4.10.2 AnGes MG, Inc. Business Overview
- 4.10.3 AnGes MG, Inc. Angiopoietin 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AnGes MG, Inc. Angiopoietin 2 Product Portfolio
- 4.10.5 AnGes MG, Inc. Recent Developments
5 Global Angiopoietin 2 Market Scenario by Region
- 5.1 Global Angiopoietin 2 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Angiopoietin 2 Sales by Region: 2021-2032
- 5.2.1 Global Angiopoietin 2 Sales by Region: 2021-2026
- 5.2.2 Global Angiopoietin 2 Sales by Region: 2027-2032
- 5.3 Global Angiopoietin 2 Revenue by Region: 2021-2032
- 5.3.1 Global Angiopoietin 2 Revenue by Region: 2021-2026
- 5.3.2 Global Angiopoietin 2 Revenue by Region: 2027-2032
- 5.4 North America Angiopoietin 2 Market Facts & Figures by Country
- 5.4.1 North America Angiopoietin 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Angiopoietin 2 Sales by Country (2021-2032)
- 5.4.3 North America Angiopoietin 2 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Angiopoietin 2 Market Facts & Figures by Country
- 5.5.1 Europe Angiopoietin 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Angiopoietin 2 Sales by Country (2021-2032)
- 5.5.3 Europe Angiopoietin 2 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Angiopoietin 2 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Angiopoietin 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Angiopoietin 2 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Angiopoietin 2 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Angiopoietin 2 Market Facts & Figures by Country
- 5.7.1 South America Angiopoietin 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Angiopoietin 2 Sales by Country (2021-2032)
- 5.7.3 South America Angiopoietin 2 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Angiopoietin 2 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Angiopoietin 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Angiopoietin 2 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Angiopoietin 2 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Angiopoietin 2 Sales by Type (2021-2032)
- 6.1.1 Global Angiopoietin 2 Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Angiopoietin 2 Sales Market Share by Type (2021-2032)
- 6.2 Global Angiopoietin 2 Revenue by Type (2021-2032)
- 6.2.1 Global Angiopoietin 2 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Angiopoietin 2 Revenue Market Share by Type (2021-2032)
- 6.3 Global Angiopoietin 2 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Angiopoietin 2 Sales by Application (2021-2032)
- 7.1.1 Global Angiopoietin 2 Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Angiopoietin 2 Sales Market Share by Application (2021-2032)
- 7.2 Global Angiopoietin 2 Revenue by Application (2021-2032)
- 7.2.1 Global Angiopoietin 2 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Angiopoietin 2 Revenue Market Share by Application (2021-2032)
- 7.3 Global Angiopoietin 2 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Angiopoietin 2 Value Chain Analysis
- 8.1.1 Angiopoietin 2 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Angiopoietin 2 Production Mode & Process
- 8.2 Angiopoietin 2 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Angiopoietin 2 Distributors
- 8.2.3 Angiopoietin 2 Customers
9 Global Angiopoietin 2 Analyzing Market Dynamics
- 9.1 Angiopoietin 2 Industry Trends
- 9.2 Angiopoietin 2 Industry Drivers
- 9.3 Angiopoietin 2 Industry Opportunities and Challenges
- 9.4 Angiopoietin 2 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst